Cancer Biology

Anthony Letai discusses how understanding programmed cell death can guide the selection of cancer treatments. The seminar explains how apoptotic signalling can be measured and how these measurements can identify drugs capable of killing cancer cells. Hybrid: New Research Building Auditorium, Georgetown University Medical Center, Washington, DC, and Zoom. Monday 5 October 2026, 16:30–17:30 EDT (America/New_York; UTC−4). Use the attendance registration form or the event’s Zoom link on the organizer page. Organized by Georgetown’s Distinguished Scientist Seminar Series. Letai is Director of the National Cancer Institute. An in-person reception follows the seminar.

This EMBO-EMBL symposium connects fundamental mechanisms of DNA replication and genome maintenance with human health and disease. Researchers from molecular biology, genetics, chromatin, replication stress and genome stability meet in Heidelberg and online for talks, discussion and scientific exchange.

Columbia's half-day symposium examines neural mechanisms in brain, gastrointestinal, pancreatic, and lung cancers. The program spans neuron-glioma crosstalk, tumor-induced neurological dysfunction, cancer pain circuits, peripheral nervous-system structure, metabolism, and therapeutic targets.

This EMBO | EMBL Symposium brings cancer researchers together to examine how tumours spread and resist treatment. Topics include circulating and metastasis-initiating cells, invasion, epigenetic regulation, dormancy, cellular plasticity, immune escape and the tumour microenvironment. The programme connects biological mechanisms with imaging, single-cell and spatial profiling, computational analysis and disease models. The event runs from 10 to 13 November 2026 at the EMBL Advanced Training Centre in Heidelberg, with virtual participation available. Abstract submissions are closed. On-site registration closes on 29 September; virtual registration remains available until 3 November. Registration fees and the two booking routes are listed on the organizer page.

Cancer Research UK offers short-term support for clinicians, nurses and allied health professionals to gain early-career cancer-research experience and generate preliminary data before applying for a PhD or MD fellowship.

Anthony Letai discusses how understanding programmed cell death can guide the selection of cancer treatments. The seminar explains how apoptotic signalling can be measured and how these measurements can identify drugs capable of killing cancer cells. Hybrid: New Research Building Auditorium, Georgetown University Medical Center, Washington, DC, and Zoom. Monday 5 October 2026, 16:30–17:30 EDT (America/New_York; UTC−4). Use the attendance registration form or the event’s Zoom link on the organizer page. Organized by Georgetown’s Distinguished Scientist Seminar Series. Letai is Director of the National Cancer Institute. An in-person reception follows the seminar.

This EMBO | EMBL Symposium brings cancer researchers together to examine how tumours spread and resist treatment. Topics include circulating and metastasis-initiating cells, invasion, epigenetic regulation, dormancy, cellular plasticity, immune escape and the tumour microenvironment. The programme connects biological mechanisms with imaging, single-cell and spatial profiling, computational analysis and disease models. The event runs from 10 to 13 November 2026 at the EMBL Advanced Training Centre in Heidelberg, with virtual participation available. Abstract submissions are closed. On-site registration closes on 29 September; virtual registration remains available until 3 November. Registration fees and the two booking routes are listed on the organizer page.